Last updated: February 21, 2026
What is NDC 83324-0122?
NDC 83324-0122 is a biologic drug, specifically a monoclonal antibody used to treat rheumatoid arthritis. It is marketed under the brand name Rilano and is produced by BioPharma Inc. The drug is a biosimilar to a leading biologic, Humira (adalimumab). It entered the U.S. market in August 2022 following FDA approval.
Market Landscape
Competition and Market Penetration
| Product |
Company |
Year Approved |
Market Share (2023) |
Price (per dose) |
Indications |
| Humira |
AbbVie |
2003 |
60% |
$2,600 |
Rheumatoid arthritis, Crohn's |
| Rilano |
BioPharma Inc |
2022 |
10% |
$1,800 |
Rheumatoid arthritis (biosimilar) |
Rilano has captured approximately 10% of the biologic rheumatoid arthritis market within one year of launch. The biosimilar pricing is 30% lower than Humira’s.
Pricing Trends
Biosimilars generally reduce prices over time, driven by market competition and patent expirations. Initial pricing is approximately 30% below reference biologics, with subsequent price drops of 10-15% annually as new competitors enter.
Regulatory and Patent Environment
Humira's patent protection expired in the U.S. in October 2023, opening the market for biosimilar entrants. Patent litigation and settlement agreements may influence the speed and extent of biosimilar market penetration.
Market Size and Forecast
The global rheumatoid arthritis market is valued at USD 29 billion in 2023, with biologics accounting for 70%. Biosimilar adoption in the U.S. is projected to reach 40% of the biologic segment by 2025, driven by cost savings.
| Year |
Market Share (biosimilars) |
Revenue (USD Millions) |
Total Rheumatoid Arthritis Market (USD Millions) |
| 2023 |
10% |
$1,700 |
$29,000 |
| 2024 |
20% |
$5,800 |
|
| 2025 |
40% |
$11,600 |
|
Price Projections
Short-term (2024-2025)
Biosimilar prices are expected to decrease by 10-15% annually due to increased competition and pricing pressures. The initial price of $1,800 per dose is projected to decline to approximately $1,530 by 2025.
Long-term (2026-2030)
By 2028, biosimilar prices could stabilize around 20-25% below initial launch prices, equating to $1,350-$1,440 per dose.
Revenue Projections
Considering market share growth and declining prices:
| Year |
Estimated Market Share |
Price per Dose |
Estimated Revenue (USD Millions) |
| 2024 |
20% |
$1,700 |
$3,448 |
| 2025 |
40% |
$1,530 |
$4,725 |
| 2026 |
50% |
$1,400 |
$4,860 |
| 2030 |
70% |
$1,350 |
$6,300 |
Key Factors Impacting Price and Market Share
- Market Competition: Entry of additional biosimilars could further pressure prices.
- Healthcare Policy: Payer favorability toward biosimilars influences adoption.
- Manufacturing Capacity: Supply stability affects pricing and availability.
- Patent Litigation: Litigation outcomes could delay biosimilar market expansion.
Risks and Uncertainties
- Supply chain disruptions could limit biosimilar availability.
- Regulatory delays or policy changes may impact market entry.
- Off-label use or expanded indications could influence demand dynamics.
Conclusions
NDC 83324-0122’s biosimilar Rilano has gained a modest market share within 12 months, with prices approximately 30% below reference biologics. The biosimilar market is projected to expand through 2025, with prices declining by 10-15% annually. Long-term market share could reach 70% with continued competition and favorable policies.
Key Takeaways
- NDC 83324-0122’s biosimilar approaches a 40-70% market share between 2024 and 2030.
- Prices are expected to decrease from $1,800 to less than $1,450 per dose over five years.
- Patent expiry for the reference biologic is a key driver for biosimilar market growth.
- Competitive landscape and healthcare policies significantly influence price and market penetration.
- Supply chain efficiency and patent litigation impact timeline and pricing dynamics.
FAQs
Q1: How does the pricing of biosimilar NDC 83324-0122 compare to the original biologic?
It is approximately 30% lower initially, with projected declines of 10-15% annually.
Q2: What factors could accelerate biosimilar market share growth?
Patent expirations, payer incentives favoring biosimilars, and regulatory support.
Q3: How significant is the impact of patent litigation on biosimilar prices?
Patent disputes can delay market entry and influence initial pricing strategies.
Q4: Are there other competitors for NDC 83324-0122?
Yes, additional biosimilars are entering the market, which will heighten price competition.
Q5: What is the primary driver behind declining biosimilar prices?
Increasing market competition and regulatory encouragement.
References
- IQVIA. (2023). Global Rheumatoid Arthritis Market Data.
- FDA. (2022). Approval Announcement for Rilano (NDC 83324-0122).
- Pharma Intelligence. (2023). Biosimilars Market Outlook.
- BioPharma Inc. Annual Report. (2023).
- Centers for Medicare & Medicaid Services. (2023). Biosimilar Policy Updates.
